BioScience Health Innovations, Inc. (BHIC)

AI-Powered SEC Filing Analysis

Quarterly Report Filed: 2026-05-11

Key Insights

  • Revenue declined 39% year-over-year in Q1 2026 ($751K vs $1.23M in Q1 2025), indicating significant business contraction and challenging market conditions for the company.
  • The company swung from profitability to a net loss of $230K in Q1 2026 despite gross margin remaining relatively stable at 65%, driven primarily by a 52% increase in operating expenses ($716K vs $469K).
  • Cash position improved to $1.15M from $662K at year-end 2025, but this is offset by new debt of $460K taken on during the quarter, suggesting potential liquidity stress requiring external financing.
  • Accounts receivable dropped dramatically from $399K to $78K while inventory increased 160% to $874K, raising concerns about sales conversion efficiency and potential inventory obsolescence risk.
  • As a non-accelerated filer and smaller reporting company with emerging growth status, BHIC has limited analyst coverage and institutional investor interest, which may contribute to limited capital availability.
Current Report Filed: 2026-04-02

Key Insights

  • The company has appointed Daniel Schmidt, the Chief Technology Officer, to its Board of Directors, indicating his growing influence and involvement in the company's strategic direction.
  • The departure of Justin Earl from the Board of Directors does not appear to be due to any disagreement with the company, suggesting it was an amicable transition.
  • Daniel Schmidt has extensive experience in therapeutic medical devices and treatments, which could help drive the company's product development and commercialization efforts.
Annual Report Filed: 2026-03-30

Key Insights

  • The company is an emerging growth company and has not been subject to all public reporting requirements, which could impact transparency and investor confidence.
  • The company has a history of losses and may need to raise additional capital in the future, which could lead to dilution for existing shareholders.
  • The company has identified cybersecurity as a key risk factor, indicating potential vulnerabilities that could impact operations and financial performance.

Filings on this page are at least 90 days old. In the app, any new BioScience Health Innovations, Inc. filing is analysed the moment you open it.

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.